echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: The vincristine-irinotecan regimen plus temozolomide can improve the survival prognosis of patients with relapsed/refractory rhabdomyosarcoma

    J Clin Oncol: The vincristine-irinotecan regimen plus temozolomide can improve the survival prognosis of patients with relapsed/refractory rhabdomyosarcoma

    • Last Update: 2021-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Once rhabdomyosarcoma (RMS) recurs, it is often insensitive to existing treatments, resulting in an overall survival rate of less than 20%
    .


    The main prognostic factors after recurrence are the type of recurrence, previous radiotherapy, initial tumor size, and time to recurrence after diagnosis


    The VIT-0910 trial aims to evaluate the efficacy and safety of vincristine-irinotecan with or without temozolomide (VIT or VI) in the treatment of relapsed or refractory rhabdomyosarcoma
    .

    This is a randomized phase 2 trial.
    RMS patients aged 0.
    5-50 years received a 21-day course of vincristine + irinotecan ± temozolomide until the disease progressed or intolerable toxicity appeared
    .


    The primary endpoint is the objective response rate after two courses of treatment


    Corrected PFS and OS for the two treatment groups

    Corrected PFS and OS for the two treatment groups

    A total of 120 patients (60 in each group) were recruited from 37 medical centers
    .


    The median age of the tested patients was 11 years (range 0.


    The objective response rates of the VIT group and VI group were 44% vs 31%, respectively.


    Toxic reaction and relative risk ratio of the two groups

    Toxic reaction and relative risk ratio of the two groups

    In general, patients in the VIT group experienced more adverse events of grade 3 and above than those in the VI group (98% vs 78%; P=0.
    009), and there were also significant differences in hematological toxicity (81% vs 61%; P= 0.
    025)
    .

    In summary, the addition of temozolomide to the VI regimen can improve the chemotherapy effect of recurrent rhabdomyosarcoma , but the accompanying toxicity also increases
    .


    The VIT regimen is considered to be the new standard treatment for patients with pediatric soft tissue sarcoma in Europe


    The addition of temozolomide to the VI regimen can improve the chemotherapy effect of recurrent rhabdomyosarcoma .


    Original source:

    Anne-Sophie Defachelles, et al.


    Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.